Immunotherapy, Inflammation and Colorectal Cancer

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death, often challenging to treat, particularly in advanced stages.
• While chemotherapy and targeted therapies have advanced CRC treatment, the survival rate for metastatic CRC remains low.
• Immunotherapy, including immune checkpoint inhibitors (ICI), shows efficacy in specific CRC subtypes (dMMR-MSI-H).

Purpose of the Study:

• To review the current status of immunotherapies for colorectal cancer (CRC).
• To explore the potential of immunotherapies, including ICI, vaccination, and adoptive T cell therapy (ATC), in various CRC subtypes.
• To investigate the application of immunotherapy in mismatch repair proficient and microsatellite instability low (pMMR-MSI-L) CRC.

Main Methods:

• Review of current scientific literature and clinical data on CRC immunotherapies.
• Analysis of the efficacy of immune checkpoint inhibitors (ICI) in different CRC molecular subtypes.
• Examination of vaccination and adoptive T cell therapy (ATC) approaches in CRC treatment.

Main Results:

• Immune checkpoint inhibitor therapy (ICI) demonstrates significant promise in mismatch repair deficient and microsatellite instability high (dMMR-MSI-H) CRC.
• The efficacy of ICI and other immunotherapies in mismatch repair proficient and microsatellite instability low (pMMR-MSI-L) CRC requires further extensive exploration.
• Current survival rates for metastatic CRC highlight the need for novel and broadly applicable treatment strategies.

Conclusions:

• Immunotherapy represents a rapidly evolving and promising frontier in colorectal cancer treatment.
• Expanding the application of immunotherapies beyond dMMR-MSI-H CRC could significantly improve patient outcomes.
• Further research into vaccination and adoptive T cell therapy (ATC) is crucial for comprehensive CRC management.